Literature DB >> 19672855

Validity of computerized diagnoses, procedures, and drugs for inflammatory bowel disease in a northern California managed care organization.

Liyan Liu1, James E Allison, Lisa J Herrinton.   

Abstract

PURPOSE: Resources for studying inflammatory bowel disease (IBD) are needed in evaluations of drug safety including traditional drugs and new biologics agents. We developed an IBD registry, with ascertainment from computerized visit information.
OBJECTIVE: We sought to characterize the positive predictive value (PPV) of IBD case-finding using computerized data compared with chart review.
METHODS: We identified 2906 persons aged 89 years or younger with one or more IBD diagnoses in computerized visit data during the period of 1996-2002. The diagnosis of IBD was confirmed through chart review. Adopting chart review as the gold standard, the validity of computerized encounter data to determine IBD was estimated.
RESULTS: Among the 2906 study subjects with one or more ICD-9 diagnosis codes of 555 or 556 in computerized data, 81% were confirmed as having IBD by chart review. Defining cases as those who underwent two or more visits without regard to diagnostic procedures or drug utilization maximized the correct classification of cases (PPV, 95%).
CONCLUSIONS: The quality of IBD diagnoses in computerized data is adequate to meet the aims of a wide range of research studies. (c) 2009 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2009        PMID: 19672855     DOI: 10.1002/pds.1824

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  21 in total

1.  Racial and ethnic differences in health care utilization and outcomes among ulcerative colitis patients in an integrated health-care organization.

Authors:  Dan Li; Bernadette Collins; Fernando S Velayos; Liyan Liu; James D Lewis; James E Allison; Nicole T Flowers; Susan Hutfless; Oren Abramson; Lisa J Herrinton
Journal:  Dig Dis Sci       Date:  2013-10-31       Impact factor: 3.199

2.  Timing of myelosuppression during thiopurine therapy for inflammatory bowel disease: implications for monitoring recommendations.

Authors:  James D Lewis; Oren Abramson; Monina Pascua; Liyan Liu; Laura M Asakura; Fernando S Velayos; Susan M Hutfless; James E Alison; Lisa J Herrinton
Journal:  Clin Gastroenterol Hepatol       Date:  2009-07-22       Impact factor: 11.382

3.  Improving case definition of Crohn's disease and ulcerative colitis in electronic medical records using natural language processing: a novel informatics approach.

Authors:  Ashwin N Ananthakrishnan; Tianxi Cai; Guergana Savova; Su-Chun Cheng; Pei Chen; Raul Guzman Perez; Vivian S Gainer; Shawn N Murphy; Peter Szolovits; Zongqi Xia; Stanley Shaw; Susanne Churchill; Elizabeth W Karlson; Isaac Kohane; Robert M Plenge; Katherine P Liao
Journal:  Inflamm Bowel Dis       Date:  2013-06       Impact factor: 5.325

4.  Inflammatory bowel disease and risk of Parkinson's disease in Medicare beneficiaries.

Authors:  Alejandra Camacho-Soto; Anat Gross; Susan Searles Nielsen; Neelendu Dey; Brad A Racette
Journal:  Parkinsonism Relat Disord       Date:  2018-02-09       Impact factor: 4.891

5.  Provision of contraceptive services to women with diabetes mellitus.

Authors:  Eleanor Bimla Schwarz; Debbie Postlethwaite; Yun-Yi Hung; Eric Lantzman; Mary Anne Armstrong; Michael A Horberg
Journal:  J Gen Intern Med       Date:  2011-09-16       Impact factor: 5.128

6.  Perioperative Timing of Infliximab and the Risk of Serious Infection After Elective Hip and Knee Arthroplasty.

Authors:  Michael D George; Joshua F Baker; Jesse Yenchih Hsu; Qufei Wu; Fenglong Xie; Lang Chen; Huifeng Yun; Jeffrey R Curtis
Journal:  Arthritis Care Res (Hoboken)       Date:  2017-11-02       Impact factor: 4.794

7.  Associations of Inflammatory Bowel Disease and Subsequent Cancers in a Population-Based Study of Older Adults in the United States.

Authors:  Jeanny H Wang; Monica D'Arcy; Edward L Barnes; Neal D Freedman; Eric A Engels; Minkyo Song
Journal:  JNCI Cancer Spectr       Date:  2021-12-23

Review 8.  Challenges in designing a national surveillance program for inflammatory bowel disease in the United States.

Authors:  Millie D Long; Susan Hutfless; Michael D Kappelman; Hamed Khalili; Gilaad G Kaplan; Charles N Bernstein; Jean Frederic Colombel; Corinne Gower-Rousseau; Lisa Herrinton; Fernando Velayos; Edward V Loftus; Geoffrey C Nguyen; Ashwin N Ananthakrishnan; Amnon Sonnenberg; Andrew Chan; Robert S Sandler; Ashish Atreja; Samir A Shah; Kenneth J Rothman; Neal S Leleiko; Renee Bright; Paolo Boffetta; Kelly D Myers; Bruce E Sands
Journal:  Inflamm Bowel Dis       Date:  2014-02       Impact factor: 5.325

9.  Development and validation of a registry-based definition of eosinophilic esophagitis in Denmark.

Authors:  Evan S Dellon; Rune Erichsen; Lars Pedersen; Nicholas J Shaheen; John A Baron; Henrik T Sørensen; Mogens Vyberg
Journal:  World J Gastroenterol       Date:  2013-01-28       Impact factor: 5.742

10.  Proton Pump Inhibitors, H2 Blocker Use, and Risk of Inflammatory Bowel Disease in Children.

Authors:  Naomi R M Schwartz; Susan Hutfless; Lisa J Herrinton; Laura B Amsden; Helene B Fevrier; Matthew Giefer; Dale Lee; David L Suskind; Joseph A C Delaney; Amanda I Phipps
Journal:  J Pediatr Pharmacol Ther       Date:  2019 Nov-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.